Brii Biosciences ^Competitor

Brii Biosciences Limited is a biotechnology company listed on the Hong Kong Stock Exchange, focused on developing innovative therapies for significant public health challenges. The company addresses unmet medical needs, particularly in infectious diseases and central nervous system disorders. With operations in key biotech hubs like Raleigh-Durham, the San Francisco Bay Area, Beijing, and Shanghai, Brii Biosciences leverages global expertise to advance its mission.

The company has a robust pipeline of therapeutic candidates, primarily targeting hepatitis B virus (HBV) infection. Their lead programs include the HBV Functional Cure Program, featuring candidates such as BRII-179, a recombinant protein-based immunotherapeutic, Elebsiran (BRII-835, VIR-2218), an HBV-targeting siRNA, and Tobevibart (BRII-877), a broadly neutralizing monoclonal antibody. Brii Biosciences also explores treatments for HIV, NTM lung disease, and anxiety and depressive disorders. The leadership team, led by Zhi Hong, Ph.D., emphasizes collaboration, as seen in their partnership with Vir Biotechnology.